Stopping Tysabri May Worsen MS

THURSDAY, Sept. 13 (HealthDay News) -- People suffering from multiple sclerosis who stopped taking the controversial drug Tysabri experienced a resurgence of brain lesions associated with their disease, researchers report.

But experts countered that the study was a small one and needs further confirmation.

"It's a valid report, [but] the study only involved 21 people," noted Dr. Randall Light, clinical assistant professor of family and community medicine with the Texas A&M Health Science Center College of Medicine and a neurologist with the Texas Brain and Spine Institute. "It's a heads-up for other researchers to share information," said Light, who was not involved in the study.

"This is an observation that needs further investigation and confirmation," agreed another expert, Dr. John Richert, executive vice president of research and clinical programs at the National Multiple Sclerosis Society in New York City.

Patients currently taking the drug should not discontinue it without seeking advice, the experts stressed.

"People taking the drugs should talk to a neurologist before," Light continued. "For patients, it just means don't stop taking the drug without talking to your doctor."

The findings were published Sept. 12 in the online edition of Neurology.

Tysabri (natalizumab), a monoclonal antibody, has been placed under a cloud of controversy for some time. The drug works by attaching itself to white blood cells called lymphocytes and preventing them from entering the brain, where they do damage that causes the disabling symptoms of MS. Tysabri had also been used to treat Crohn's disease.

But the drug has a checkered past. It first received U.S. Food and Drug Administration approval in November 2004, only to be pulled from the market three months later after several patients in clinical trials developed a rare but deadly viral infection of the brain called progressive multifocal leukoencephalopathy.

In June 2006, the FDA allowed the drug to return to the market, but with strict conditions. According to the new guidelines, Tysabri can only be administered by approved doctors, at infusion sites and pharmacies that register and comply with a patient-safety program designed by Biogen-IDEC, the maker of Tysabri, and approved by the FDA.

According to the U.S. National Institutes of Health, multiple sclerosis is an unpredictable disease of the central nervous system that can range from relatively benign to somewhat disabling, to devastating, as communication between the brain and other parts of the body is disrupted.

Many researchers believe MS to be an autoimmune disease, one in which the body, through its immune system, launches a defensive attack against its own tissues. In the case of MS, it is nerve-insulating myelin tissue that is under assault.

This trial was initiated after a neuroradiologist noticed that some patients were developing new lesions (as evidenced on MRI) after their Tysabri was discontinued.

All participants in this trial had had MRIs of their brains taken before starting Tysabri. They then had another such scan taken an average of 15 months after receiving the last infusion of the drug.

Participants were divided into two groups -- one which had taken the drug for an average of three years and one which had taken Tysabri for an average of only two months.

Page
  • 1
  • |
  • 2
Join the Discussion
blog comments powered by Disqus
 
You Might Also Like...